Basic Information
| LncRNA/CircRNA Name | LINC01638 |
| Synonyms | NA |
| Region | GRCh38_22:27221349-27224727 |
| Ensemble | ENSG00000233521 |
| Refseq | NM_001350812 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP |
| Sample | triple negative breast cancer tissues, cell lines (MCF-10A, T47D, MCF7, BT474, SKBR3, ZR-75-30, ZR-75-1, MDA-MB-231, BT549, and HCC1937) |
| Expression Pattern | up-regulated |
| Function Description | LINC01638 is highly expressed in TNBC tissues and cells. LINC01638 maintains the mesenchymal traits of TNBC cells, including an enriched epithelial-mesenchymal transition (EMT) signature and cancer stem cell-like state. LINC01638 knockdown suppresses tumor proliferation and metastasis both in vitro and in vivo. LINC01638 overexpression predicts a poor outcome of breast cancer patients. Mechanistically, LINC01638 interacts with c-Myc to prevent SPOP-mediated c-Myc ubiquitination and degradation. C-Myc transcriptionally enhances MTDH (metadherin) expression and subsequently activates Twist1 expression to induce EMT. Our findings describe LINC01638-mediated signal transduction and highlight the crucial role of LINC01638 in TNBC progression. |
| Pubmed ID | 30002443 |
| Year | 2018 |
| Title | LINC01638 lncRNA Activates MTDH-Twist1 Signaling by Preventing SPOP-mediated c-Myc Degradation in Triple-Negative Breast Cancer |
External Links
| Links for LINC01638 | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |